Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), has become an integral component of weight management and type 2 diabetes treatment due to its potent efficacy in glycemic control and cardiovascular risk reduction
What cost-saving programs are available for FDA-approved options
Platelet counts and concentrations of fasting blood sugar (FBS), hemoglobin A1c (HbA1c), immunoreactive insulin (IRI), high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, non-esterified fatty acids (NEFA), aspartate aminotransferase (AST), ALT, -glutamyl transpeptidase, ferritin, and type IV collagen 7 were measured using standard laboratory techniques before and after glutathione treatment
Hadley et al., Discovery and development of the novel melanogenic drugs, in Integration of Pharmaceutical Discovery and Development: Case Studies, edited by Borchardt et al., Plenum Press, New York (1998)
Based on the Phase 2 trajectory data (Jastreboff et al., NEJM 2023), individuals at the 12 mg dose had lost approximately 8-10% of their body weight by week 12
Based on current research, once approved, retatrutide may be considered for: Adults with obesity or who are overweight with related health conditions People with type 2 diabetes who also need weight management support Those with weight related joint problems such as knee osteoarthritis People with obstructive sleep apnoea linked to excess weight, an area where early trial data has also shown encouraging results As with any medicine of this kind, it will not be suitable for everyone, and decisions will need to involve a doctor once it becomes available
US$ 24.06
US$ 25.38
US$ 22.54
